Tedizolid in skin and skin structure infections: brave new world?

Click to increase image sizeClick to decrease image size

Declaration of interest

P. Panagopoulos has been an advisory board member of Gilead Science and Merck Sharp and Dohme, has received honoraria by AbbVie, Gilead Science, Merck Sharp and Dohme and Novartis and attended conferences sponsored by Actelion, Janssen, Bristol-Myers Squibb, Merck Sharp and Dohme and Gilead. N Papanas has been an advisory board member of Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GlaxoSmithKline, Merck Sharp and Dohme, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, ELPEN, Merck Sharp and Dohme, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and attended conferences sponsored by TrigoCare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. E Maltezos has participated in sponsored studies by Astra-Zeneca, GlaxoSmithKline, Novo Nordisk, Novartis and Sanofi-Aventis; and attended conferences sponsored by Wyeth, Pfizer, and Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.